Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Abacavir is a widely-used nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) infection. Mandatory postmarketing surveillance was conducted in Korea to monitor the safety and evaluate the effectiveness of Ziagen® (abacavir sulfate 300 mg; ViiV Healthcare, Middlesex, UK). Materials and Methods: An open-label, multi-center, non-interventional postmarketing surveillance study was conducted from June 2010 to June 2016 to monitor the safety and effectiveness of Ziagen across 12 hospitals in Korea. Subjects older than 18 years taking Ziagen according to prescribing information were enrolled. The primary outcome was defined as the occurrence of any adverse events after Ziagen administration. Secondary outcomes included the occurrence of adverse drug reactions, occurrence of serious adverse events, and effectiveness of Ziagen administration. Results: A total of 669 patients were enrolled in this study, with a total observation period of 1047.8 person-years. Of these, 90.7% of patients were male. The mean age of patients was 45.8±11.9 years. One-hundred ninety-six (29.3%) patients reported 315 adverse events, and four patients reported seven serious adverse events, without any fatal events. There was one potential case of an abacavir hypersensitivity reaction. Among the 97 adverse drug reactions that were reported from 75 patients, the most frequent adverse drug reactions included diarrhea (12 events), dyspepsia (10 events), and rash (9 events). No ischemic heart disease was observed. In the effectiveness analysis, 91% of patients achieved HIV-1 RNA under 50 copies/mL after 24 months of observation with abacavir administration.
Abstract
Background: Abacavir is a widely-used nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) infection. Mandatory postmarketing surveillance was conducted in Korea to monitor the safety and evaluate the effectiveness of Ziagen® (abacavir sulfate 300 mg; ViiV Healthcare, Middlesex, UK). Materials and Methods: An open-label, multi-center, non-interventional postmarketing surveillance study was conducted from June 2010 to June 2016 to monitor the safety and effectiveness of Ziagen across 12 hospitals in Korea. Subjects older than 18 years taking Ziagen according to prescribing information were enrolled. The primary outcome was defined as the occurrence of any adverse events after Ziagen administration. Secondary outcomes included the occurrence of adverse drug reactions, occurrence of serious adverse events, and effectiveness of Ziagen administration. Results: A total of 669 patients were enrolled in this study, with a total observation period of 1047.8 person-years. Of these, 90.7% of patients were male. The mean age of patients was 45.8±11.9 years. One-hundred ninety-six (29.3%) patients reported 315 adverse events, and four patients reported seven serious adverse events, without any fatal events. There was one potential case of an abacavir hypersensitivity reaction. Among the 97 adverse drug reactions that were reported from 75 patients, the most frequent adverse drug reactions included diarrhea (12 events), dyspepsia (10 events), and rash (9 events). No ischemic heart disease was observed. In the effectiveness analysis, 91% of patients achieved HIV-1 RNA under 50 copies/mL after 24 months of observation with abacavir administration.
참고문헌 (29)
- Staszewski S, "A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects", AIDS, 12, pp.F197~F202 (1998)
- Staszewski S, "Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial", JAMA, 285, pp.1155~1163 (2001)
- Walmsley SL, "Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection", N Engl J Med, 369, pp.1807~1818 (2013)
- DeJesus E, "Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults", Clin Infect Dis, 39, pp.1038~1046 (2004)
- 대한에이즈학회, "국내 HIV 감염인의 HIV", AIDS 진단 및 치료에 관한 임상진료지침 권고안, 2011, pp.43(2), 89~128[DOI]
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"[URL]
- Günthard HF, "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel", JAMA, 316, pp.191~210 (2016)
- Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir", N Engl J Med, 358, pp.568~579 (2008)
- Choi AI, "Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons", AIDS, 25, pp.1289~1298 (2011)
- Cruciani M, "Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data", AIDS, 25, pp.1993~2004 (2011)
- Ding X, "No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis", J Acquir Immune Defic Syndr, 61, pp.441~447 (2012)
- Rasmussen LD, "Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study", AIDS, 25, pp.1637~1646 (2011)
- "The use of the WHOUMC system for standardised case causality assessment"[URL]
- National Kidney Foundation, "KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update", Am J Kidney Dis, 66, pp.884~930 (2015)
- 대한에이즈학회, "The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-Infected Koreans, 2015, pp.47(3), 205~211[DOI]
- "Annual report on the notified HIV/AIDS in Korea"[URL]
- "Annual report on the notified HIV/AIDS in Korea"[URL]
- Boettiger DC, "Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database", PLoS One, 9, pp.e106525~ (2014)
- 김민정, "Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching", Infection and Chemotherapy, 47(4), pp.231~238 (2015), 대한감염학회
- Kurita T, "Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan", Pharmacoepidemiol Drug Saf, 23, pp.361~371 (2014)
- Bannister WP, "Incidence of abacavir hypersensitivity reactions in euroSIDA", Antivir Ther, 13, pp.687~696 (2008)
- Hetherington S, "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir", Clin Ther, 23, pp.1603~1614 (2001)
- Saag M, "High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients", Clin Infect Dis, 46, pp.1111~1118 (2008)
- Young B, "First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America", AIDS, 22, pp.1673~1675 (2008)
- Rauch A, "Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study", Clin Infect Dis, 43, pp.99~102 (2006)
- Sun HY, "Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan", J Antimicrob Chemother, 60, pp.599~604 (2007)
- Phillips EJ, "Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?", Clin Infect Dis, 43, pp.103~105 (2006)
- Park WB, "Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?", Clin Infect Dis, 48, pp.365~367 (2009)
- Kurita T, "Safety analysis of Epzicom® (lamivudine", abacavir sulfate) in post-marketing surveillance in Japan, 2014, pp.23, 372~381